EMAP, a tumor-derived antiangiogenic and antiendothelial cytokine, in our experience exhibited antitumor effects in several tumor types including PDAC [28], [30], [31], [34], [35], [45], [46]. This evidence concerns the gene EML1 and neoplasm.